TY - JOUR
T1 - A diagnostic marker to discriminate childhood apraxia of speech from speech delay
T2 - Ii. validity studies of the pause marker
AU - Shriberg, Lawrence D.
AU - Strand, Edythe A.
AU - Fourakis, Marios
AU - Jakielski, Kathy J.
AU - Hall, Sheryl D.
AU - Karlsson, Heather B.
AU - Mabie, Heather L.
AU - McSweeny, Jane L.
AU - Tilkens, Christie M.
AU - Wilson, David L.
N1 - Publisher Copyright:
© 2017 American Speech-Language-Hearing Association.
PY - 2017/4
Y1 - 2017/4
N2 - Purpose: The purpose of this 2nd article in this supplement is to report validity support findings for the Pause Marker (PM), a proposed single-sign diagnostic marker of childhood apraxia of speech (CAS). Method: PM scores and additional perceptual and acoustic measures were obtained from 296 participants in cohorts with idiopathic and neurogenetic CAS, adult-onset apraxia of speech and primary progressive apraxia of speech, and idiopathic speech delay. Results: Adjusted for questionable specificity disagreements with a pediatric Mayo Clinic diagnostic standard, the estimated sensitivity and specificity, respectively, of the PM were 86.8% and 100% for the CAS cohort, yielding positive and negative likelihood ratios of 56.45 (95% confidence interval [CI]: [1.15, 2763.31]) and 0.13 (95% CI [0.06, 0.30]). Specificity of the PM for 4 cohorts totaling 205 participants with speech delay was 98.5%. Conclusion: These findings are interpreted as providing support for the PM as a near-conclusive diagnostic marker of CAS.
AB - Purpose: The purpose of this 2nd article in this supplement is to report validity support findings for the Pause Marker (PM), a proposed single-sign diagnostic marker of childhood apraxia of speech (CAS). Method: PM scores and additional perceptual and acoustic measures were obtained from 296 participants in cohorts with idiopathic and neurogenetic CAS, adult-onset apraxia of speech and primary progressive apraxia of speech, and idiopathic speech delay. Results: Adjusted for questionable specificity disagreements with a pediatric Mayo Clinic diagnostic standard, the estimated sensitivity and specificity, respectively, of the PM were 86.8% and 100% for the CAS cohort, yielding positive and negative likelihood ratios of 56.45 (95% confidence interval [CI]: [1.15, 2763.31]) and 0.13 (95% CI [0.06, 0.30]). Specificity of the PM for 4 cohorts totaling 205 participants with speech delay was 98.5%. Conclusion: These findings are interpreted as providing support for the PM as a near-conclusive diagnostic marker of CAS.
UR - http://www.scopus.com/inward/record.url?scp=85017519720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017519720&partnerID=8YFLogxK
U2 - 10.1044/2016_JSLHR-S-15-0297
DO - 10.1044/2016_JSLHR-S-15-0297
M3 - Article
C2 - 28384803
AN - SCOPUS:85017519720
SN - 1092-4388
VL - 60
SP - S1118-S1134
JO - Journal of Speech, Language, and Hearing Research
JF - Journal of Speech, Language, and Hearing Research
IS - 4
ER -